Table 1.
Incidence of ACLF in patients with different previous NUCs treatment experiences
| NUCs experiences | HBV DNA ad-level (IU/ml), n (%) |
Log (HBV DNA), mean ± SD | MELD scores, mean ± SD | ACLF development, n (%) | ||||
|---|---|---|---|---|---|---|---|---|
| <2000 | ≥2000 | n | before admission | after admission | Total | |||
| naïve | 26 (29.5) | 62 (70.5) | 4.55 ± 1.71 | 19.7 ± 8.9 | 88 | 22 (25.0) | 11 (12.5) | 33 (37.5) |
| maintained | 8 (66.7) | 4 (33.3) | 2.27 ± 2.48 | 17.5 ± 9.9 | 12 | 2 (16.7) | 3 (25.0) | 5 (41.7) |
| interrupted | 2 (18.2) | 9 (81.8) | 5.40 ± 1.90 | 15.4 ± 8.8 | 11 | 2 (18.2) | 3 (27.3) | 5 (45.5) |
| Total | 36 (32.4) | 75 (67.6) | 4.39 ± 1.97 | 19.0 ± 9.0 | 111 | 26 (23.4) | 17 (15.3) | 43 (38.7) |
1. NUCs experiences: naïve: antiviral treatment-naïve patients; maintained: patients with sustained long-term NUCs treatments till admission; interrupted: patients with interruption or discontinuation of antiviral treatment after long-term of NUCs therapies
2. HBV DNA ad-level <2000 IU/ml or ≥ 2000 IU/ml: Fisher’s exact test, P = 0.032
3. Log(HBV DNA) (logarithm of the serum HBV DNA ad-level): F = 10.150, P = 0.000
4. MELD scores (MELD scores at admission): F = 1.301, P = 0.276
5. ACLF development: Fisher’s exact test, P = 0.549; ACLF vs No-ACLF: χ2 = 0.309, P = 0.828; ACLF after admission vs No-ACLF: Fisher’s exact test, χ2 = 2.083, P = 0.353; ACLF before admission vs No-ACLF: Fisher’s exact test, P = 1.000